Cost-effectiveness of pharmacist-led care versus usual care in type 2 diabetic Jordanians: a Markov modeling of cardiovascular diseases prevention.

Expert Review of Pharmacoeconomics & Outcomes Research
Rimal Mousa, Eman Hammad

Abstract

Cardiovascular diseases (CVDs) are responsible for one third of global deaths and the main cause of death among Jordanians. Pharmacist-led care was outlined previously as a cost-effective approach in the management of chronic illness; however, this is not well studied in low to middle-income countries. To assess the cost-effectiveness of pharmacist-led care versus usual care in preventing CVDs in Type 2 Diabetes Mellitus (T2DM). A Markov model of one-year cycle length and 10-year time horizon was constructed to simulate 10-year CVD events, mortality, and costs for two hypothetical cohorts; usual care and pharmacist-led care, respectively, of Jordanian patients suffering from T2DM. Public health provider perspective was adopted. Outcomes examined were incremental costs, LYGs, and incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analysis (PSA) assessed the robustness of the results. The pharmacist-led care generated an additional 0.3 LYG/patient at an additional cost of JD1,238.78 (US$1,747.24) comparing to the usual care in the 10-year base-case analysis. Deterministic and PSA supported the robustness of base-case findings, indicating that pharmacist-led care is cost-effective. The finding...Continue Reading

References

Mar 1, 2003·Diabetes Care·Jaana Lindström, Jaakko Tuomilehto
Dec 23, 2003·Cost Effectiveness and Resource Allocation : C/E·Raymond HutubessyTessa Tan-Torres Edejer
May 30, 2007·Archives of Internal Medicine·Peter W F WilsonRalph B D'Agostino
Apr 17, 2008·Journal of Diabetes and Its Complications·Kamel AjlouniMohammed El-Khateeb
Apr 10, 2009·Journal of the American Pharmacists Association : JAPhA·Toni FeraWilliam M Ellis
Jun 26, 2009·British Journal of Clinical Pharmacology·Nadia Rashid Al MazrouiJames C McElnay
Apr 9, 2014·The EPMA Journal·Olga GolubnitschajaVincenzo Costigliola
Nov 26, 2015·Bulletin of the World Health Organization·Faris DababnehRobert Anderson
Nov 2, 2016·The EPMA Journal·Olga GolubnitschajaVincenzo Costigliola
Dec 19, 2016·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Beth WoodsKarl Claxton
Dec 21, 2016·Bulletin of the World Health Organization·Melanie Y BertramSuzanne R Hill
Nov 9, 2017·Saudi Medical Journal·Eman A HammadAmal A Akour
Jan 11, 2018·BMC Family Practice·Rebecca ReynoldsNicholas Zwar
Apr 26, 2018·Journal of Managed Care & Specialty Pharmacy·Heather OurthAnthony P Morreale
Jun 1, 2018·BioMed Research International·Charbel Abi KhalilKamel Mohammedi
Jun 10, 2018·Diabetes Research and Clinical Practice·Seung Min ChungJea Young Lee
Jun 14, 2018·The EPMA Journal·Alexandre Assuane DuarteOlga Golubnitschaja
Jul 15, 2018·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Thomas R EinarsonUlrik H Panton
Sep 21, 2018·Frontiers in Public Health·Shazia Q JamshedAkshaya S Bhagavathula
Nov 27, 2019·European Journal of Preventive Cardiology·Giel NijpelsPetra J Elders

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Annals of Family Medicine
Wei C YuetRandy D Martin
Journal of Oncology Practice
Stephen A BernardGary S Winzelberg
Journal of the American Pharmacists Association : JAPhA
Jeffrey P Bratberg
© 2021 Meta ULC. All rights reserved